LeMaitre Vascular (LMAT)

• Market cap: $2.04B
• 1 day: -2.01%
• 5 days: 1.39%
• 1 month: 8.15%
• 3 months: -9.40%
• 6 months: 1.90%
• Year to date: -0.80%
• 1 year: 40.03%
• 5 years: 218.50%
• 10 years: 901.55%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Employees: 630

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 24

27% more repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 95

24% more call options, than puts

Call options by funds: $332K | Put options by funds: $267K

5% more funds holding

Funds holding: 288 [Q3] → 303 (+15) [Q4]

1.26% more ownership

Funds ownership: 92.92% [Q3] → 94.18% (+1.26%) [Q4]

1% more capital invested

Capital invested by funds: $1.94B [Q3] → $1.95B (+$11.6M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $95 5% upside
• Avg. target: $105 16% upside
• High target: $110 21% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Lake Street Brooks O'Neil 50% 1-year accuracy 8 / 16 met price target	21% upside $110	Buy Maintained	28 Feb 2025
Citizens Capital Markets Daniel Stauder 45% 1-year accuracy 5 / 11 met price target	21% upside $110	Buy Maintained	28 Feb 2025
Wells Fargo Nathan Treybeck 0% 1-year accuracy 0 / 3 met price target	5% upside $95	Equal-Weight Initiated	13 Feb 2025